First clinical trials of Sputnik V and COVID-19 Vaccine AstraZeneca
The Ministry of Healthcare of Republic of Azerbaijan granted an approval to conduct clinical trials of the combined use of the Sputnik V and the COVID 19 vaccine AstraZeneca in Azerbaijan.
Previously, the Gamaleya National Center, RDIF, AstraZeneca and R-Pharm signed an agreement to cooperate on COVID-19 vaccine development, which was announced in December 2020.
The trial will take place in several countries
The research aims to evaluate the immunogenicity and safety of the Sputnik V and AstraZeneca vaccines combined use, states R-Pharm.
The research program will take place in several countries, enrolling 100 adults aged 18 years and older.
"R-Pharm has been actively working with the Republic of Azerbaijan for several years, we opened a modern production facility here in 2019, later in 2020 we registered two drugs from our anti-Covid portfolio: Artlegia and Coronavir. This pilot study is vital for developing of a new approach to the prevention of COVID-19, moreover the leading scientific and clinical centers of Azerbaijan will be able to make their own important contribution in this direction," says Alexey Repik, the R-Pharm Chairman of the Board.
Clinical trials will begin by the end of February.
The Ministry of Healthcare of Republic of Azerbaijan granted an approval to conduct clinical trials of the combined use of the Sputnik V and the COVID 19 vaccine AstraZeneca in Azerbaijan.
Previously, the Gamaleya National Center, RDIF, AstraZeneca and R-Pharm signed an agreement to cooperate on COVID-19 vaccine development, which was announced in December 2020.
The trial will take place in several countries
The research aims to evaluate the immunogenicity and safety of the Sputnik V and AstraZeneca vaccines combined use, states R-Pharm.
The research program will take place in several countries, enrolling 100 adults aged 18 years and older.
“R-Pharm has been actively working with the Republic of Azerbaijan for several years, we opened a modern production facility here in 2019, later in 2020 we registered two drugs from our anti-Covid portfolio: Artlegia and Coronavir. This pilot study is vital for developing of a new approach to the prevention of COVID-19, moreover the leading scientific and clinical centers of Azerbaijan will be able to make their own important contribution in this direction,” says Alexey Repik, the R-Pharm Chairman of the Board.
Clinical trials will begin by the end of February.
Published: February 10, 2021
